Oliver Rosen is a physician-scientist and has broad experience in biopharmaceutical oncology and hematology product development, including global clinical development, global medical affairs, translational medicine, patient advocacy, and health economics and outcomes research (HEOR). He is passionate about successful translation of data from bench to bedside to develop medicines that address unmet medical needs.
He is the CMO of Akamis Bio and served previously in the C-suite at DynamiCure, SQZ Biotechnologies and Deciphera Pharmaceuticals. At SQZ, his work led to achieving proof of concept in the clinic for an autologous PBMC-based antigen presenting cell platform and a red blood cell-based cancer vaccine. At Deciphera, he took four small molecules into the clinic, and his work led to the full approval of QINLOCK™. Before joining Deciphera, he held senior clinical development and medical affairs roles including at Millennium: The Takeda Oncology Company and Genentech.
Oliver Rosen received his medical training in oncology and hematology at the University Hospital Charité in Berlin. His academic career focus was on the first applications of autologous stem-cell transplants in patients with refractory autoimmune diseases and on the systematic administration of prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in adults with hematological malignancies. Prior to his clinical training, he participated in a post-doctoral program in Molecular and Cellular Biology at the University of Hamburg and holds an M.D. from the University of Cologne, Germany.